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Abstract
In 2005, the first evidence of an allosteric binding site at the CB1R was provided by the identification of three
indoles of the company Organon that were allosteric enhancers of agonist binding affinity and, functionally, al-
losteric inhibitors of agonist activity. Since then, structure–activity relationships of indoles as CB1R modulators
have been reported. Targeting the allosteric site on CB1R, new families structurally based on urea and on 3-
phenyltropane analogs of cocaine have been discovered as CB1R-negative allosteric modulators (NAMs), respec-
tively, by Prosidion and by the Research Triangle Park. Endogenous allosteric ligands of different nature have
been identified more recently. Thus, the therapeutic neuroprotection application of lipoxin A4, an arachidonic
acid derivative, as an allosteric enhancer of CB1R activity has been confirmed in vivo. It was also the case of
the steroid hormone, pregnenolone, whose negative allosteric effects on D9-tetrahydrocannabinol (D9-THC)
were reproduced in vivo in a behavioral tetrad model and in food intake and memory impairment assays. Curi-
ously, the peroxisome proliferator-activated receptor-c agonist fenofibrate or polypeptides such as pepcan-12
have been shown to act on the endocannabinoid system through CB1R allosteric modulation. The mechanistic
bases of the effects of the phytocannabinoid cannabidiol (CBD) are still not fully explained. However, there is
evidence that CBD behaves as an NAM of D9-THC- and 2-AG. Allosteric modulation at CB1R offers new oppor-
tunities for therapeutic applications. Therefore, further understanding of the chemical features required for allo-
steric modulation as well as their orthosteric probe dependence may broaden novel approaches for fine-tuning
the signaling pathways of the CB1R.
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Introduction
One traditional way of designing new drugs is the so-
called one target–one disease approach. Indeed, this
is the case of many commercially available drugs,
which interact with enzymes, receptors, or ionic chan-
nels among others. One of the most important targets
are the G-protein-coupled receptors (GPCRs) for
which agonists and antagonist/inverse agonists have
been developed.
These traditional ligands bind to the same site as the
endogenous ligand, the so-called orthosteric site. How-
ever, recently, research has shifted to compounds that
can interact with a different region of the receptor,
termed the allosteric site, since this approach may re-
sult in pharmacological advantages such as higher
specificity and thus reduced side effects. The best
known mechanisms of action of these allosteric ligands
are activation or inhibition of the receptor signaling, re-
ferred to as positive allosteric modulators (PAMs) and
negative allosteric modulators (NAMs). There are also
neutral or silent ligands, silent allosteric modulators,
which do bind to the allosteric site without affecting
the response of the endogenous agonist. In addition,
bitopic ligands that bind to both the orthosteric and
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allosteric sites have been described. In the last years,
there has been considerable research in allosteric mod-
ulation of GPCRs both in academia and industry,1,2
and structural knowledge on how these interactions
take place has advanced on the basis that some cocrys-
tals of a ligand bound to an allosteric site have been
obtained.3
In addition to two allosteric modulators marketed
for HIV and hyperparathyroidism, recent potential
therapeutic applications of allosteric modulators of
GPCRs include central nervous system (CNS) disor-
ders such as neurodegenerative diseases or schizophre-
nia4 and also pain for which PAMs of the l-opioid
receptor have been proposed.5
A particular kind of GPCRs are the cannabinoid CB1
and CB2 receptors (CB1R and CB2R), for which thou-
sands of traditional ligands, belonging to many differ-
ent chemical structures, have been synthesized and
evaluated. However, this has had only limited success
in bringing them to the clinic. In fact, only three natu-
ral derived medicines (Marinol, Nabilone, and
Sativex) are available largely due to their unwanted
side effects.
One possibility to overcome the limitations of these
traditional cannabinoids interacting with the orthos-
teric sites would be to use allosteric cannabinoid li-
gands. Despite the considerable research undertaken
on traditional cannabinoid agonists and antagonists,
there have been comparatively few reports on allosteric
cannabinoid ligands. In this review, we will give an
overview of the chemical structures that have been
tested and proven to be allosteric cannabinoid ligands,
but will not deeply deal with the pharmacological as-
pects of cannabinoid allosterism, which has been cov-
ered elsewhere.6–9 According to structural features,
CB1R allosteric modulators reported to date can be
classified as follows: indole derivatives; urea derivatives;
and structures acting as endogenous ligands and mis-
cellaneous structures.
Indole Derivatives
The first evidence for an allosteric binding site on CB1R
was revealed in 2005 by pharmacological studies realized
on three indoles from the company Organon Research,
Org27569, Org29647, and Org27759 (Fig. 1).10 Among
them, Org27569 has been more widely studied and is
considered as a prototypical CB1R allosteric modulator.
Org27569 behaves as a positive allosteric enhancer of
agonist binding, whereas in terms of functionality,
Org27569 is considered a NAM. Lately, the effect of
Org27569 as a NAM has been confirmed in a neuronal
model of endocannabinoid synaptic transmission.11
However, when tested in vivo, Org27569 lacked efficacy
in modulating the action of orthosteric cannabinoids.12
Thus, controversial pharmacological data led to a very
recent study in which the allosteric effects of Org27569
at CB1R have been revealed to be pathway specific and
time dependent, suggesting a more complex process
than initially proposed.13
The Org27569-binding site has been determined by
Shore et al.14 using a combination of molecular model-
ing, mutation, and functional assays. This site was iden-
tified in the CB1R transmembrane helix (TMH)3–6–7
region. Org27569 acts by modulating receptor activity
through conformational changes in the receptor. The
authors described how Org27569 sterically blocked
FIG. 1. Structure of indoles Org27569 (pharmacological profile in Table 1), Org29647, and Org27759.
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movements of the extracellular loops and TMH6 that are
involved in receptor activation. Recently, site-directed
fluorescence labeling studies reported by Fay et al.15
showed that effectively TMH6 movements are associ-
ated with G-protein activation, whereas its attached
helix eight could be involved in the binding of arrestin
triggering the biased signaling pathway.
Following discovery of Org27569, structure–activity
relationship (SAR) studies were reported by various re-
search groups confirming that indole-2-carboxamide
was a good scaffold for developing allosteric modulators
for CB1R. However, it was only in 2012 that Piscitelli
et al.16 reported that the first indole-2-carboxamides
structurally correlated with Org27569. The very close de-
rivative of Org27759, the indole 1 (Fig. 2), was found to
possess the highest positive stimulation of the series on
the orthosteric agonist CP-55,940 binding at CB1R.
A large number of Org27569 analogs have been iden-
tified inKendall andLu’s laboratories.17–19 Among them,
it is worthy to mention compound 2, the 3-pentyl-1H-
indole-2-carboxamide derivative (Fig. 2), as an allosteric
enhancer of [3H]-CP-55,940 binding with a markedly
high binding cooperativity factor and potent antagonism
of agonist-induced GTPcS binding.18 Interestingly, the
hexyl and the propyl derivatives of 2 induced b-arrestin
1-mediated pathway-biased signaling.19
Very recently, a novel series of 1H-indole 2-
carboxamides has been reported by Nguyen et al.20
The most potent compound 3 (Fig. 2) is reported as
a NAM of CP-55,940 at CB1R according to calcium
mobilization assays.
After a first generation of Org27569 derivatives, new
series of 2-phenyl-1H-indoles have been identified as
PAMs at CB1R. Compound PAM1, also named as
GAT211, displayed in Figure 2, exemplifies the series
of 3-(2-nitro-1-arylethyl)-1H-indoles claimed by Tha-
kur et al.21 as PAMs for CB1R in cAMP functional as-
says. Due to the presence of a chiral center, GAT211 is
a racemic mixture of two optical isomers (R and S) that
were isolated using supercritical fluid chromatography.
FIG. 2. Indole derivatives as CB1R allosteric modulators: 1, 2, 3, ABD1027, PAM1 (GAT211), and ZCZ011
(pharmacological profile in Table 1). *Race MIC mixture.
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Difference in pharmacology potencies of both enantio-
mers could be appreciated.
Ignatowska-Jankowska et al.22 reported the pharmaco-
logical properties of 6-methyl-3-[2-nitro-1-(thiophen-2-
yl)ethyl]-2-phenyl-1H-indole (ZCZ011; Fig. 2). ZCZ011
increased [3H]-CP-55,940 binding and potentiated
anandamide (AEA)-stimulated signaling in [35S]-GTPcS
binding, b-arrestin recruitment, and extracellular signal-
regulated kinase (ERK) phosphorylation assays. A very
interesting finding is that PAM effects of ZCZ011 could
be confirmed by in vivo assays. The indole ZCZ011
exhibited antinociceptive effects in neuropathic and in-
flammatory pain models with no associated cannabimi-
metic effects.
Greig et al.23 from the University of Aberdeen ap-
plied the bioisosteric replacement of carboxamide by
sulfonamide leading to numerous N-arylalkyl-1H-
indole-2-sulfonic amides claimed in a patent. Inventors
reported that ABD1027 (Fig. 2) did not affect [3H]-CP-
55,940 binding, although it inhibited agonist signaling
in functional b-arrestin recruitment assays.
Urea Derivatives
In 2007, the company Prosidion identified a novel
class of CB1R allosteric compounds through high-
throughput screening of a small library.24 The lead
optimized urea of this series, PSNCBAM-1 (Fig. 3), in-
creased CB1R agonist binding and behaved as an allo-
steric antagonist in [35S]-GTPcS binding and cAMP
assays. In this study, acute food intake experiments
provided the first in vivo data showing the effi-
cacy of CB1R allosteric antagonism similar to the an-
tiobesity effects of the well-known CB1R antagonist,
SR141716.
In 2015, 8 years after the discovery of PSNCBAM-1,
the first SAR studies on PSNCBAM-1 were published
by German et al.25 The resulting analogs showed simi-
lar pharmacological profiles to the parent NAM in
binding and calcium mobilization assays. Structural
modifications have focused on the pyridine and the
4-chlorophenyl groups. Substituted amine with small
size alkyl chains showed to be preferred for pyridine
substitution. Substitution in position 4 of the phenyl
ring with an electrowithdrawing group was revealed
to be important for activity (compound 4; Fig. 3).
In the same year, Thakur et al.26 claimed novel CB1R
allosteric modulators based on PSNCBAM-1 structure.
SAR studies involving bioisosterism of urea were exten-
sively examined with the synthesis and evaluation of
carbamates, thioureas, 1,3,4-oxadiazol-2-amines, and
3,4-diaminocyclobut-3-ene-1,2-diones, leading to func-
tionally selective NAMs. The 3,4-diaminocyclobut-
3-ene-1,2-dione derivative, GAT358, was selected for
in vivo behavioral tests that suggested minimal CB1R in-
verse agonist-related side effects.
Endogenous CB1R Allosteric Modulators
In addition to synthetic allosteric modulators catego-
rized herein, endogenous molecules of diverse chemical
nature have been identified as allosteric modulators of
CB1Rs.
One of these molecules is lipoxin A4 (Fig. 4), an oxy-
genated derivative of arachidonic acid involved in
immune system regulation and known as a potent en-
dogenous anti-inflammatory mediator. However, the
specific effects of lipoxin A4 in the CNS were reported
to be mediated by unknown mechanisms. In 2012, lip-
oxin A4 was proposed as an allosteric modulator of
FIG. 3. PSNCBAM-1 and its analogs as CB1R allosteric modulators: GAT358 and 4 (pharmacological profile in
Table 1).
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CB1R by Pamplona et al.
27 This lipid acted as a CB1R
PAM, enhancing receptor binding of AEA and [3H]-
CP-55,940 and not only potentiating selectively AEA-
versus 2-AG in HEK293-CB1R cells but also in the
behavioral tetrad tests. The authors confirmed the ther-
apeutic application for neuroprotection of lipoxin A4 as
an allosteric enhancer of CB1R activity in an in vivo
model of b-amyloid-induced spatial memory impair-
ment. Recently, Staiker et al.11 reported that lipoxin
A4 surprisingly exhibited a CB1R NAM profile, and
no PAM as reported so far, in a neuronal model of 2-
AG-mediated depolarization-induced suppression of ex-
citation (DSE). Thus, this effect could be attributable to a
potential probe dependence of lipoxin A4. Adding to the
complexity, recent studies realized by Khajehali et al.13
on lipoxin A4 could not corroborate the PAM modula-
tory effects on either AEA- or CP-55,940-mediated
cAMP inhibition in CHO-CB1R cells.
Another putative endogenous allosteric modulator
at the CB1R is the steroid hormone pregnenolone
(Fig. 4), a hydrophobic precursor for all C18, C19, and
C21 steroids directly synthesized from cholesterol.
The therapeutic known targets for pregnenolone are
GABA and NMDA receptors.28 However, in 2014,
Valle´e et al.29 identified pregnenolone as an allosteric
inhibitor at CB1Rs decreasingD
9-tetrahydrocannabinol
(D9-THC)-induced ERK1/2 phosphorylation in CHO-
CB1R cells. Furthermore, these NAM effects on D
9-
THC were reproduced in vivo in a behavioral tetrad
model, in food intake and memory impairment assays.
In contrast, in the neuronal model reported by Staiker
et al.,11 pregnenolone failed to modulate 2-AG of syn-
aptic transmission. Likewise, Khajehali et al.13 reported
lack of modulatory effect of pregnenolone on either D9-
THC- or WIN55,212–2-induced activation of ERK1/2
phosphorylation. These divergent data suggest probe-
or pathway-dependent allosteric effects.
Until recently, synthetic or endogenous compounds
acting on the endocannabinoid system (ECS) were of
lipid nature. In 2012, Bauer et al.30 described a 12-
amino acid sequence, structurally corresponding to
an N-terminal extended form of hemopressin, as a po-
tent CB1R NAM of orthosteric agonist-induced cAMP
accumulation, [35S]-GTPcS binding, and receptor in-
ternalization. This polypeptide, named pepcan-12,
has been recently localized in discrete cells of the
FIG. 4. Endogenous CB1R allosteric modulators: lipoxin A4, pregnenolone, and pepcan-12 (pharmacological
profile in Table 1).
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CNS and adrenal gland.31 It is worth mentioning that
this endocannabinoid peptide was previously reported
to interact with CB1R as an agonist.
32 Furthermore, the
NAM profile of pepcan-12 has been confirmed in the
DSE study of 2-AG synaptic transmission performed
by Staiker et al.11
Miscellaneous CB1R Allosteric Modulators
The interest gained in this field led to the identification
of an assorted range of other small molecules that also
display CB1R allosteric modulation.
In 2009, researchers from the Research Triangle
Park screened several 3-phenyltropane analogs of co-
caine for their activity at the CB1R.
33 These molecules
had been previously characterized as dopamine trans-
porter (DAT) inhibitors.34 Among this series, the tro-
panes, RTI-371 and RTI-370, and the benztropine
JHW007 (Fig. 5) stand out as PAMs of CP-55,940-
induced CB1R activity in a cell-based calciummobiliza-
tion assay. RTI-371 was found to be of special interest
because it is a potent and selective DAT inhibitor that
lacks cocaine-like behavioral effects and abuse liability.
According to the authors, these atypical cocaine-related
effects could be due to positive allosteric modulation of
the CB1R.
33 This study highlights the potential of the 3-
phenyltropane scaffold for the development of novel
CB1R PAMs.
The nonpsychoactive phytocannabinoid cannabidiol
(CBD; Fig. 5) has shown diverse promising therapeutic
applications through multiple biological targets. CBD is
known to interact with many nonendocannabinoid sig-
naling systems such as the opioid receptors, the transient
channel receptor, transient receptor potential channel
1, or the nuclear receptor, peroxisome proliferator-
activated receptor (PPAR)-c, among others. CBD does
not bind to the orthosteric CB1R binding site; however,
it has been shown to display antagonism of CB1R ago-
nists in vitro.35–37 More recently, Laprairie et al.38
provided evidence that CBD behaved as an NAM of
D9-THC- and 2-AG-dependent CB1R internalization,
b-arrestin recruitment, and phospholipase C b3- and
ERK1/2-phosphorylation. These results may explain
some of the in vivo effects of this promising nonpsy-
choactive compound providing novel insights in the in-
triguing pharmacology of CBD.
The close relationship between the ECS and the PPARs
led to explore the activity of the PPAR-a agonist, fenofi-
brate39 (Fig. 5), in the ECS. This fibrate is an amphipathic
molecule that acts as a prodrug formed by fenofibric acid
linked to an isopropyl ester. Priestley et al.40 reported the
pharmacological profile of fenofibrate at CBRs. [35S]-
GTPcS binding experiments revealed partial agonism
of fenofibrate at CB1R and full agonism at CB2R. More-
over, at higher concentrations, this PPAR-a ligand was
FIG. 5. Miscellaneous CB1R allosteric modulators: RTI370, RTI371, JHW007, cannabidiol (CBD), and fenofibrate
(pharmacological profile in Table 1).
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also able to significantly decrease [35S]-GTPcS binding of
CP-55,940 acting as an NAM of CB1R. Thus, the authors
suggested two possible interpretations. Fenofibrate could
be considered a bitopic ligand at CB1R since it binds both
orthosteric and allosteric sites or fenofibrate could be an
allosteric CB1R modulator that could be able to produce
by itself a functional response by interacting with a non-
orthosteric site at CB1R.
Conclusions and Perspectives
The psychoactive side effects generated by activation of
CB1R in the brain have limited the use of orthosteric
CB1R ligands as drugs. However, this receptor plays
an important role in diverse processes such as pain,
cognition, and metabolism. Alternative targets within
the ECS have been proposed, including CB2R, the
fatty acid amide hydrolase, or the monoacylglycerol li-
pase. Allosteric modulation at CB1R offers new oppor-
tunities for therapeutic applications. Even though the
first CB1R allosteric ligand, Org27569, was identified
in 2005, significant interest by the research community
only started few years ago. Then, there have been rapidly
increasing research efforts directed into CB1R alloster-
ism during these last 3 years. This review reflects the
Table 1. Summary of CB1R Allosteric Modulators and Their Cannabinoid Pharmacological Profile
Compound
CB1R/CB2R
orthosteric modulation
CB1R allosterism
CB1R allosteric
modulation Functional outcome (orthosteric ligand) References
Org27569 CB1R inverse agonist
6 NAM [35S]-GTPcS binding assaya (CP-55,940; AEA), cAMP
assay, b-arrestin recruitmenta (CP-55,940;
WIN55,212, AEA)
Price et al. 200510
PAM ERK1/2 phosphorylationa (CP-55,940) Baillie et al. 20136
NAM ERK1/2 phosphorylationa (2-AG) Khajehali et al. 201513
NAM DSEc (2-AG) Straiker et al. 201511
2 — NAM [35S]-GTPcS binding assayb (CP-55,940) Mahmoud et al. 201318
3 — NAM Ca2+ mobilization assaya (CP-55,940) Nguyen et al. 201520
PAM1 (GAT211) — PAM cAMP assay (CP-55,940) Thakur et al. 201321
ZCZ011 CB1R agonist
22 PAM [35S]-GTPcS binding assayd (CP-55,940; AEA) Ignatowska-Jankowska
et al. 201522
NE cAMP assaya (CP-55,940; AEA)
PAM ERK1/2 phosphorylationa (CP-55,940; AEA)
PAM b-arrestin recruitmentb (AEA)
ABD1027 — NAM b-arrestin recruitmentb (CP-55,940) Greig et al. 201223
PSNCBAM-1 CB1R partial inverse agonist
24 NAM [35S]-GTPcS binding assayb (CP-55,940; AEA), cAMP
assayb (CP-55,940; AEA)
Horswill et al. 200724
NAM [35S]-GTPcS binding assaye (CP-55,940; WIN55,212) Wang et al. 201141
NAM b-arrestin recruitmenta (CP-55,940; WIN55,212) Baillie et al. 20136
NAM DSEc (2-AG) Straiker et al. 201511
4 — NAM Ca2+ mobilization assayf (CP-55,940) German et al. 201425
GAT358 — NAM cAMP assay (CP-55,940), b-arrestin recruitmentb
(CP-55,940)
Thakur et al. 201526
Lipoxin A4 NE27 PAM cAMP assayb (AEA) Pamplona et al. 201227
NAM DSEc (2-AG) Straiker et al. 201511
NE cAMP assaya (AEA; CP-55,940) Khajehali et al. 201513
Pregnenolone — NAM ERK1/2 phosphorylationa (D9-THC) Valle´e et al. 201429
NE DSEc (2-AG) Straiker et al. 201511
NE ERK1/2 phosphorylationa (D9-THC, WIN55,212) Khajehali et al. 201513
Pepcan 12 CB1R agonist
32 NAM cAMP assay, [35S]-GTPcS binding, CB1R
internalizationa (2-AG, WIN55,212, HU210)
Bauer et al. 201230
NAM DSEc (2-AG) Straiker et al. 201511
RTI-371 NE33 PAM Ca2+ mobilization assaya (CP-55,940) Navarro et al. 200933
CBD Weak CB1R/CB2R antagonist
36,37 NAM PLCb3- and ERK1/2 phosphorylation, b-arrestin
recruitmentb,g (D9-THC, 2-AG)
Laprairie et al. 201538
Fenofibrate CB1R partial agonist/CB2R agonist
40 NAM [35S]-GTPcS bindinga (CP-55,940) Priestley et al. 201540
aCHO-CB1R cells.
bHEK293-CB1R.
cHippocampal neurons.
dMouse brain membranes.
eCerebellar membranes.
fRD-HGA16-CB1R cells.
gSTHdhQ7/Q7-CB1R.
D9-THC, D9-tetrahydrocannabinol; AEA, anandamide; CBD, cannabidiol; DSE, depolarization-induced suppression of excitation; ERK, extracellular
signal-regulated kinase; NAM, negative allosteric modulator; NE, no effect; PAM, positive allosteric modulator; PLC, phospholipase C.
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structural diversity and nature of the CB1R allosteric
modulators identified so far. In particular, there has
been an increasing identification of endogenous alloste-
ric modulators that offer new insights in the intriguing
pharmacology of CB1R. In Table 1, a summary of the
pharmacological profile of diverse CB1R allosteric
modulators is displayed. It is worth mentioning that
in several of the studies discussed above, there is no
correlation between the different cell-based pharmaco-
logical data. Moreover, the in vitro data do not always
translate to in vivo effects. These divergent functional
data may account for signaling-specific allosteric mod-
ulation as well as orthosteric probe dependence. Subse-
quently, there is a clear need for developing more
allosteric pharmacological tools for understanding
this complex pharmacology.
The characterization of small molecules as allosteric
modulators of CB1Rs provides the basis for future de-
sign and synthesis of optimized allosteric modulators.
Efforts need to be made to expand these scaffolds
and obtain structural information about the ligand–
allosteric site interactions. Further understanding of
the chemical features required for allosteric modula-
tion as well as their orthosteric probe dependence
may broaden novel approaches for fine-tuning the sig-
naling pathways of the CB1R.
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Abbreviations Used
2-AG¼ 2-arachidonylglycerol
AEA¼ anandamide
CB1R¼ cannabinoid receptor 1
CB2R¼ cannabinoid receptor 2
CBD¼ cannabidiol
CNS¼ central nervous system
DAT¼ dopamine transporter
DSE¼ depolarization-induced suppression of excitation
ECS¼ endocannabinoid system
ERK¼ extracellular signal-regulated kinase
GPCR¼G-protein-coupled receptor
NAM¼ negative allosteric modulator
PAM¼ positive allosteric modulator
PLC¼ phospholipase C
PPAR¼ peroxisome proliferator-activated receptor
SAR¼ structure–activity relationship
TMH¼ transmembrane helix
D9-THC¼D9-tetrahydrocannabinol
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